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PolymorphismBackground: Coronary artery disease (CAD) is the most prevalent form of cardiovascular disease that is
caused by the formation of plaque in the arteries walls. Both genetic and environmental factors play
an important role in the development of CAD.
Aim: The aim of this study was to determine the association of 5,10-methylenetetrahydrofolate reduc-
tase (MTHFR) C677T gene polymorphism with CAD in an Iranian population.
Subjects and methods: In this case/control study, sequence specific primer-polymerase chain reaction
(SSP-PCR) method was used for genotyping of 310 patients with CAD and 367 healthy controls.
Results: Frequency of C/T genotype was significantly higher in the patients group than the control group
(P = .03, OR: 1.6, 95% CI: 1.04–2.47). Based on the assumption that T is a risk allele, dominant model com-
pares C/C genotypes to C/T + T/T genotypes. A significant association was observed inMTHFR C677T when
the effect of the polymorphism was considered under a dominant genetic model (OR = 1.59; 95% CI = 1.03–
2.46; P = .02). Evaluating genotype frequencies in 4 different ethnic groups (Fars, Turkmen, Sistani, and
others) demonstrated significant statistical association of C/T genotype in Fars sub-groups (OR = 1.8;
95% CI = 1.11–3.06; P = .01) but this association is not observed in other populations. Significant associa-
tion of C/T (P = .01, OR: 2.21, 95% CI: 1.15–4.4) genotype was found in women, but this association was not
observed in men.
Conclusion: The results of this study showed that C/T genotype in MTHFR C677T position is a causative
factor, especially in women, and might be associated with susceptibility to CAD in the Iranian population.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Coronary artery disease (CAD) is caused by atherosclerotic
plaque build-up in the wall of coronary arteries and with decreased
blood flow [1]. CAD is the most common type of cardiovascular dis-
ease and the most important cause of death globally [2].
Previous studies have shown that both genetic and environ-
mental factors affect the incidence of this disease [3]. Factors such
as age, smoking, high blood pressure, family history, diabetes, lack
of exercise, obesity, stress, high blood cholesterol, poor diet and
excessive alcohol increase the risk of developing CAD [4,5]. Genetic
factors play a major role in CAD progression in younger people [6].
5,10-Methylenetetrahydrofolate reductase (MTHFR) gene is
located on the short (p) arm of chromosome 1 at position 36.3
(1p36.3). MTHFR reduces 5,10-methylenetetrahydrofolate to5-methyltetrahydrofolate, which is the carbon donor for re-
methylation of homocysteine to methionine [7].
Wilcken et al. reported that CAD patients have higher concen-
trations of homocysteine than healthy individuals [8]. In subse-
quent studies, Hyperhomocysteinaemia has been recognized as a
risk factor for coronary heart disease [9]. Previous investigations
reported reduced MTHFR activity with a thermo-unstable enzyme
in patients with CAD [10].
Goyette et al. found nine polymorphisms in the MTHFR gene via
single-strand conformation polymorphism and direct sequencing
of PCR fragments [11]. Using the same procedures, Frosst et al.
reported that C to T substitution at nucleotide 677 leads to alanine
to valine amino acid change at the 222nd position of MTHFR
protein (Ala222Val). In most populations, the C677T polymor-
phism (rs1801133) in MTHFR is an even more common polymor-
phism with an allele frequency of 30–40% [7,12].
Some studies reported an association between C677T polymor-
phism and risk of cardiovascular disease, while others did not find
such association [13].
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MTHFR (C677T) polymorphism in patients with CAD and healthy
individuals to provide baseline epidemiological data for future
clinical investigations of CAD and other diseases in Iran.
Iran is the 17th most populous nation in the world and has cen-
tral location in Eurasia and Western Asia [14]. Different ethnicities
live in Iran including the Persians (the largest groups) Turkic
groups (include the Turkmen and the Qashqai peoples) Kurds, Lurs,
Sistanis, Balochis, Arabs and others. Because of the ethnic diversity,
evaluating genetic variation in Iran is valuable and it may be used
in future studies.
2. Subjects and methods
2.1. Patients
In this case-control study, the frequency of MTHFR C677T gene
polymorphism was evaluated in 310 patients with CAD and 367
healthy controls. The mean age of subjects in the case and control
group was 59.25 ± 10.54 and 51.94 ± 10.88 years respectively. The
percentages of men and female was 60.32% and 39.68% in the cases
and 35.62% and 64.38% in the controls respectively. Control sub-
jects were matched with patients by age, ethnicity, and geograph-
ical area.
CAD patients were diagnosed by angiography test and approved
by a cardiologist, fromMarch 2013 to March 2014, at Kowsar Heart
Center in Kordkuy, Iran. Inclusion criteria for patients group was
coronary stenosis of 70% and more in at least one major coronary
artery. Patients with coronary stenosis below 70% were excluded
from the study. None of the patients had major autoimmune or
hematologic disease.
Individuals with normal angiography at rest, without symp-
toms of myocardial ischemia during exercise were selected as
controls.
All of subjects (including case and control) were divided into
four main ethnic groups of Fars, Turkmen, Sistani and others.
In agreement with the Helsinki Declaration, all participants
signed the informed consent and the Ethics Committee of Golestan
University of Medical Sciences approved this study. The sample
size was determined by the Quanto software V-1.2 with a statisti-
cal power of 80%.
2.2. DNA extraction and genotyping
Five ml peripheral whole blood was used for extracting genomic
DNA by a standard protocol [15].Table 1
Frequency of the MTHFR C677T allele and genotypes among patients (N = 310) and contro
Alleles and Genotype Controls CAD
C/C 75 (20.4 %) 43 (
C/T 267 (72.8%) 244
T/T 25 (6.8%) 23 (
C 417 (57%) 330
T 317 (43%) 290
Model of Inheritance
Dominant
C/C 75 (20.4 %) 43 (
C/T + T/T 292 (79.6%) 267
Recessive
C/T + C/C 342 (93.2%) 287
T/T 25 (6.8%) 23 (
Co-dominant
C/C + T/T 100 (27.2 %) 66 (
C/T 267 (72.8%) 244
*OR: Odds Ratio, CI: Confidence Interval, NS: Not Significant.
**The frequency of CC genotype was more in the control group and was selected as refeC677T gene polymorphism ofMTHFRwas detected based on the
specific sequence primer polymerase chain reaction (SSP-PCR)
method. Human growth hormone (HGH) gene was used as an
internal control for false-negative reactions. The polymorphism
was identified by the sequence-specific forward primers
5-GAGAAGGTGTCTGCGGGAGC-30 and 5-GAGAAGGTGTCTGCGGG
AGT-30 in combination with the consensus reverse primer 5-CTC
AATCACGTCCTTGATCTC-30 [16]. The following control primer pairs
that amplify a conserved region of the HGH were used: HGH-F:
50-GCCTTCCCAACCATTCCCTTA-30 and HGH-R: 50-TCACGGATTT
CTGTTGTGTTTC-30.
SSP-PCR amplification was done using a 15 ml reaction mixture
containing one ml of genomic DNA, 0.9 ml of 25 mm MgCl2 (Qia-
gen, USA), 1.5 ml of each 10X reaction buffer, 1.5 ml of 10 mM
dNTP, 2.2 ml of sucrose 60%, 0.5 VL-for-specific primers (10 pM),
0.5 ml of 10 pM HGH primers, and 0.2 of Taq polymerase (Qiagen,
USA).
PCR was carried out by a thermal cycler (Techne, UK), using the
following program: 1 min at 95 C followed by 10 cycles of 15 s at
94 C, 15 s at 65 C, 40 s at 72 C, followed by 20 cycles of 10 s at
94 C, 50 s at 59 C and 40 s at 72 C, with 5 min at 72 C as final
extension.
The PCR products were electrophoresed on 1.5% agarose gel
(Merck, Germany) stained with ethidium bromide. Photographs
were taken using a gel documentation system (UVITEC, UK) and
DNA bands were visualized under the UV radiation.
2.3. Statistical analysis
Statistical analysis was done using Statistical Package for the
Social Sciences (SPSS, version 17.0, IBM, USA) and the mean of
parametric variables was calculated. Allele and genotype frequen-
cies were calculated and compared between groups using non-
parametric tests, followed by exact Fisher’s analysis by STATA
V-8 (California, USA). The risk associated with genotypes/alleles
was calculated as the odds ratio (OR) with 95% confidence interval
(CI). P-value less than .05 were considered as statistically
significant.
3. Results
The allelic and genotypic distributions of the MTHFR gene
C677T in healthy controls and patients with CAD under co-
dominant, dominant and recessive models are shown in Table 1.
Frequency distributions of genotypes C/C, C/T and T/T in the
control subjects were about 20.4%, 72.8% and 6.8%, respectively.ls (N = 367) under Co-dominant, Dominant and Recessive model.
patients OR (95% CI)* P-value
13.9 %) 1 (–)** –
(78.7 %) 1.6 (1.04–2.47) .03
7.4 %) 1.6 (0.77–3.34) NS* (.2)
(53%) 1 (–) –
(47%) 1.16 (0.93–1.44) NS (.2)
13.9 %) 1 (–) –
(86.1%) 1.59 (1.03–2.46) .02
(92.6%) 1 (–) –
7.4 %) 1.1 (0.58–2.06) NS (.8)
21.3) 0.72 (0.5–1.0) NS (.07)
(78.7 %) 1 (1) –
rence group.
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about 13.9%, 78.7%, 7.4% respectively.
The frequency of C/T genotype was significantly higher in the
case group compared to the controls (P = .03, OR: 1.6, 95% CI:
1.04–2.47). Frequencies of C/C and T/T genotypes and C and T alle-
les were different between the controls and patients group but
they were not statistically significant.
Based on the assumption that T is a risk allele, dominant model
compares C/C genotypes to C/T + T/T genotypes. A significant
association was observed in MTHFR C677T when the effect of the
polymorphism was evaluated under a dominant genetic model
(OR = 1.59; 95% CI = 1.03–2.46; P = .02).
Genotype frequencies in four different ethnic groups repre-
sented significant statistical association in Fars sub-groups but this
association was not observed in other populations.
The C/T genotype frequency was significantly increased in Fars
patients compared to Fars controls (OR = 1.8; 95% CI = 1.11–3.06;
P = .01). However, there was no significant association between
T/T genotype and CAD in the Fars sub-groups (Table 2).Table 2
Frequency of the MTHFR C677T genotypes within four different ethnic groups.
Model Genotype Total Controls
Fars C/C 90 (18.9%) 57 (23.2%)
C/T 351 (73.9%) 170 (69.1%)
T/T 34 (7.2%) 19 (7.7%)
Total 475 (100.0%) 246 (100.0%
Turkmen C/C 16 (16.5%) 10 (17.9%)
C/T 73 (75.3%) 44 (78.6%)
T/T 8 (8.2%) 2 (3.6%)
Total 97 (100.0%) 56 (100.0%)
Sistani C/C 9 (12.2%) 6 (13.3%)
C/T 63 (85.1%) 37 (82.2%)
T/T 2 (2.7%) 2 (4.4%)
Total 74 (100.0%) 45 (100.0%)
Other C/C 2 (7.7%) 1 (5.9%)
C/T 20 (76.9%) 14 (82.4%)
T/T 4 (15.4%) 2 (11.8%)
Total 26 (100.0%) 17 (100.0%)
*OR: Odds Ratio, CI: Confidence Interval, NS: Not Significant.
**The frequency of CC genotype was more in the control group and was selected as refe
Table 3
Frequency of the MTHFR C677T genotypes within SEX.
Gender Genotype Controls CAD patient
Men C/C 23 (17.7%) 28 (15.0%)
C/T 99 (76.2%) 138 (73.8%)
T/T 8 (6.2%) 21 (11.2%)
Total 130 (100.0%) 187 (100.0%
Women C/C 52 (22.1%) 15 (12.2%)
C/T 166 (70.6%) 106 (86.2%)
T/T 17 (7.2%) 2 (1.6%)
Total 235 (100.0%) 123 (100.0%
*OR: Odds Ratio, CI: Confidence Interval, NS: Not Significant.
**The frequency of CC genotype was more in the control group and was selected as refe
Table 4
Genotyping investigation on patients suffering from one-, two- or three-vessel-stenosis.
Genotype Controls, n(%) 1 VD, n(%) P-value
C/C 75 (20.4%) 19 (16.7%) –
C/T 267 (72.8%) 89 (78.1%) NS (.4)
T/T 25 (6.8%) 6 (5.3%) NS (1)
VD: vessel disease; N.S: Not Significant.The frequency of C/T (P = .01, OR: 2.21, 95% CI: 1.15–4.4) geno-
type was significantly different among female subjects, while no
significant difference was found among male subjects (Table 3).
Frequencies of genotypes in CAD group according to a number
of affected arteries showed that genotype C/T was significantly
associated with the three vessel disease type (p = .05) (Table 4).
4. Discussion
Cardio- and cerebrovascular diseases are multifactorial, as their
etiopathogenesis is determined by genetic and environmental fac-
tors and by gene-gene and gene-environment interactions [17].
Several studies have investigated the association of several genes
polymorphisms and CAD [18–21].
Although data have concluded conflicting results, several stud-
ies have been carried out to test the hypothesis that genetic poly-
morphisms in the MTHFR gene might be associated with CAD risk.
Morita et al. examined the distribution of the MTHFR C677T
genotypes (Ala222Val) in 362 Japanese male patients with CADCAD patients OR (95% CI) P-value
33(14.4%) 1 (–) –
181 (79.0%) 1.8 (1.11–3.06) .01
15(6.6%) 1.36 (0.56–3.27) NS (.5)
) 229 (100.0%)
6 (14.6%) 1 (–) –
29 (70.7%) 1.1 (0.31–4.1) NS (1)
6 (14.6%) 5 (0.58–62) NS (.2)
41 (100.0%)
3 (10.3%) 1 (–) –
26 (89.7%) 1.4 (0.26–9.4) NS (.7)
0 (0.0%) 0 (0–5.7) NS (1)
29 (100.0%)
1 (11.1%) 2.3 (0.02–196) NS (.5)
6 (66.7%) 1 (–) –
2 (22.2%) 2.3 (0.13–38) NS (.5)
9 (100.0%)
rence group.
s Total OR (95% CI) P-value
51 (16.1%) 1 (–) –
237 (74.8%) 1.1 (0.59–2.2) NS (.7)
29 (9.1%) 2.2 (0.7–6.7) NS (.15)
) 317 (100.0%)
67 (18.7%) 1 (–) –
272 (76.0%) 2.21 (1.15–4.4) .01
19 (5.3%) 0.4 (0.04–2.1) NS (.3)
) 358 (100.0%)
rence group.
2VD, n(%) P-value 3VD, n(%) P-value
10 (12.3%) – 14 (12.2%) –
63 (77.8%) NS (.15) 92 (80.0%) .05
8 (9.9%) NS (.15) 9 (7.8%) NS (.19)
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higher in the patients compared to controls [22].
Study of Alam et al. on 100 patients with CAD and 100 controls
from North India, has shown the positive association of MTHFR
(C677T) gene polymorphism and risk of CAD [23].
Tripathi et al. examined 329 patients with CAD and 331 healthy
individuals from the same region and found that the frequency of T
allele was significantly higher in patients [24].
Sarecka-Hujar et al. genotyped the MTHFR C677T polymor-
phism in angiographically documented patients with premature
CAD and showed that presence of MTHFR TT genotype, smoking
or elevated levels of low-density lipoprotein cholesterol affect
the risk of premature CAD [25].
Kolling et al. demonstrated that MTHFR gene C677T polymor-
phism is not associated with CAD [26].
Meta-analyses studies on the association of MTHFR genotype
with risk of coronary heart disease showed a significant hetero-
geneity between the results obtained in different regions [27,28].
However, a meta-analysis of MTHFR case-control studies failed to
find a correlation between risk of coronary heart disease and T/T
versus C/C homozygotes for the MTHFR C677T polymorphism [9].
The present study evaluated the association of MTHFR gene
polymorphism with susceptibility to CAD in 310 Iranian patients
with CAD and 367 healthy matched controls.
In Iran, Aleyasin et al. evaluated C677TMTHFR polymorphism in
100 CAD cases and 100 healthy controls and concluded that
patients had a significantly higher frequency of T allele [29]. Nasiri
et al. genotyped 54 patients with a history of MI (Myocardial
Infarction) and 54 control subjects in Fars province of Iran and
found a strong positive correlation between the T/T genotype and
risk of myocardial infarction [30].
Saffari et al. reported no significant difference between patients
with multi-vessel CAD and subjects with less than 30% stenosis of
the main arteries in southern Iran [31].
Our results showed that distribution of the C/T genotype was
significantly different between the CAD patients and healthy con-
trols. Other genotypes showed that there was a mild difference
between the frequency of C/T and T/T genotypes and C and T allele
in CAD cases and healthy controls but they were not statistically
significant.
In the present study, genotype frequencies in the Fars ethnic
group were similar to MTHFR genotype diversity in the total study
population. However, this association was not observed in other
ethnic groups and more studies should be carried out in larger pop-
ulation to further validate the results.
Significant differences in the frequency of C/T genotype in
females indicates that the MTHFR gene may act as a major risk fac-
tor in women. It has been suggested that environmental factors
could be considered as risk factors in men. One study in south of
Iran showed that number of male CAD patients was higher than
women and concluded that sex hormones (Estrogen and proges-
terone) may play protective role in women [32].
The present study found genotype C/T is significantly associated
with the three vessel disease type but showed almost similar fre-
quencies for the C/C and T/T genotypes regarding to stenosis of
one, two or three vessels. Unlike some findings of previous studies
that showed the lack of association of genotype with the disease
[24,33–35]. Nevertheless, Morita et al. reported a significant asso-
ciation and significantly higher frequency of the mutant genotype
in patients with triple-vessel disease [22]. Mousavi et al. in Iran
showed significant association of mutant genotype with the two
and three vessel disease type [19].
The most important limitation of this study was the ethnic dif-
ferences of populations. The allelic and genotype frequency can be
significantly different in various populations. The sample size is
second limitation. It is important to perform study with a largerstatistical population to clarify the role of polymorphism in the
population.
5. Conclusion
Results of this study reported that the frequency of C/T geno-
type in MTHFR C677T position is significantly different between
the patients with CAD and healthy individuals, which might be a
causative factor and genetic risk factor for cardiovascular disease
in the Iranian population.
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